 Theravance Biopharma Incs NASDAQ: TBPH Izencitinib, a gut-selective JAK inhibitor developed for ulcerative colitis and Crohns disease, failed a key Phase 2 trial. Johnson Johnsons NYSE: JNJ pharmaceutical unit Janssen dished out 100 million upfront in a partnership with Theravance to develop Izencitinib back in 2018. 